SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/6337722A9A98ED24E15C1F6259A9A93952C7F4E39BC9C111144C1F2441A05B3F1A330AA74DF819836955F72818156F11>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/6337722A9A98ED24E15C1F6259A9A93952C7F4E39BC9C111144C1F2441A05B3F1A330AA74DF819836955F72818156F11
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/6337722A9A98ED24E15C1F6259A9A93952C7F4E39BC9C111144C1F2441A05B3F1A330AA74DF819836955F72818156F11
http://www.w3.org/2000/01/rdf-schema#comment
"MAGEC1/CT7 MAGEA3/6 and LAGE-1 are good candidates for immunotherapy since together they cover 85% of the multiple myeloma cases."
xsd:string
http://purl.uniprot.org/uniprot/#_7586B0359C7674D7B8105865C75AD1764CFC8739D9743B9E3480560968FE7DFB4777845D3029BF4F2F6A2B5DDB23F3EB
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/6337722A9A98ED24E15C1F6259A9A93952C7F4E39BC9C111144C1F2441A05B3F1A330AA74DF819836955F72818156F11
http://purl.uniprot.org/uniprot/O75638
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6337722A9A98ED24E15C1F6259A9A93952C7F4E39BC9C111144C1F2441A05B3F1A330AA74DF819836955F72818156F11
http://purl.uniprot.org/uniprot/#_O75638-mappedCitation-18237105
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6337722A9A98ED24E15C1F6259A9A93952C7F4E39BC9C111144C1F2441A05B3F1A330AA74DF819836955F72818156F11